Skip to main content

Digital tool will be tested against COVID-19 ‘brain fog’

A digital tool used to treat attention-deficit hyperactivity disorder (ADHD) is being tested to see if it can help counter lingering, fuzzy thinking in COVID-19 survivors, a condition sometimes known as ‘brain fog’.

An app called EndeavorRx – developed by PureTech Health-backed Akili Interactive – will be tested in two clinical trials to see if it can improve cognitive function in people who have recovered from COVID-19 but still show cognitive problems weeks or months later.

Brain fog is a commonly reported feature of ‘long COVID’ along with physical symptoms like extreme fatigue, chest tightness, severe headaches and limb pain, a syndrome that is not yet fully understood and still has no universally agreed definition.